KCP
NBIX icon

Kera Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Kera Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
1,360
-708
-34% -$105K 0.02% 572
2026
Q1 		$272K Sell
2,068
-120
-5% -$15.9K 0.03% 451
2025
Q4 		$298K Buy
2,188
+455
+26% +$65.9K 0.04% 407
2025
Q3 		$243K Buy
+1,733
New +$235K 0.04% 357

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kera Capital Partners's NBIX Position: Q2 2026 in Review

Kera Capital Partners reduced its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, selling an estimated $105K and leaving 1,360 shares worth $229K. The position accounts for 0.02% of the portfolio, ranked #572.

Kera Capital Partners first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $298K in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Kera Capital Partners held 1,360 shares of Neurocrine Biosciences worth $229K as of Q2 2026.
  • Kera Capital Partners sold 708 Neurocrine Biosciences shares in Q2 2026, an estimated $105K.
  • Neurocrine Biosciences made up 0.02% of Kera Capital Partners's portfolio in Q2 2026, its #572 holding.
  • Kera Capital Partners first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Kera Capital Partners's Neurocrine Biosciences position peaked at $298K in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.